MA30475B1 - Acides biphenyl carboxyliques substitutes et derives en resultant. - Google Patents

Acides biphenyl carboxyliques substitutes et derives en resultant.

Info

Publication number
MA30475B1
MA30475B1 MA31395A MA31395A MA30475B1 MA 30475 B1 MA30475 B1 MA 30475B1 MA 31395 A MA31395 A MA 31395A MA 31395 A MA31395 A MA 31395A MA 30475 B1 MA30475 B1 MA 30475B1
Authority
MA
Morocco
Prior art keywords
derivatives
carboxylic acids
substituted biphenyl
biphenyl carboxylic
compounds
Prior art date
Application number
MA31395A
Other languages
English (en)
Inventor
Francis Wilson
Alison Reid
Valerie Reader
Richard John Harrison
Mihiro Sunose
Remedios Hernadez-Perni
Jeremy Major
Cyrille Boussard
Kathryn Smelt
Jess Taylor
Adeline Leformal
Andrew Cansfield
Svenja Burckhardt
Chih Yung Ho
Yan Zhang
Original Assignee
Ortho Mcneil Pharm Inc
Cellzome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc, Cellzome Ltd filed Critical Ortho Mcneil Pharm Inc
Publication of MA30475B1 publication Critical patent/MA30475B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention a pour objet des composés présentant la formule générale (I), les définitions de X, Y, R1,R.2, R3, R4 R9, et R10 données ci-dessous, et/ou un sel ou ester en dérivant. De plus la présente invention a pour objet l'emploi desdits composés pour le traitement de la maladie d'Alzheimer et leur emploi pour la modulation de l'activité de (gamma)-sécrétase.
MA31395A 2006-04-21 2008-11-20 Acides biphenyl carboxyliques substitutes et derives en resultant. MA30475B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06112938A EP1849762B1 (fr) 2006-04-21 2006-04-21 Acides biphényl carboxyliques substitués et leurs dérivés

Publications (1)

Publication Number Publication Date
MA30475B1 true MA30475B1 (fr) 2009-06-01

Family

ID=36688012

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31395A MA30475B1 (fr) 2006-04-21 2008-11-20 Acides biphenyl carboxyliques substitutes et derives en resultant.

Country Status (35)

Country Link
US (1) US7557244B2 (fr)
EP (2) EP1849762B1 (fr)
JP (1) JP5479088B2 (fr)
KR (1) KR101542255B1 (fr)
CN (1) CN101687758B (fr)
AP (1) AP2008004656A0 (fr)
AR (1) AR060568A1 (fr)
AU (1) AU2007240335B2 (fr)
BR (1) BRPI0710656A2 (fr)
CA (1) CA2650006C (fr)
CR (2) CR10375A (fr)
CY (1) CY1109399T1 (fr)
DE (1) DE602006007810D1 (fr)
DK (1) DK1849762T3 (fr)
EA (1) EA016129B9 (fr)
ES (2) ES2328616T3 (fr)
GE (1) GEP20115269B (fr)
GT (1) GT200900120A (fr)
IL (2) IL194790A (fr)
MA (1) MA30475B1 (fr)
MX (1) MX2008013445A (fr)
MY (1) MY148953A (fr)
NO (1) NO20084517L (fr)
NZ (1) NZ573000A (fr)
PE (1) PE20080364A1 (fr)
PL (1) PL1849762T3 (fr)
PT (1) PT1849762E (fr)
SI (1) SI1849762T1 (fr)
SM (1) SMP200800061B (fr)
TN (1) TNSN08413A1 (fr)
TW (1) TWI399362B (fr)
UA (1) UA95952C2 (fr)
UY (1) UY30301A1 (fr)
WO (1) WO2007124394A1 (fr)
ZA (1) ZA200809856B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5439381B2 (ja) 2007-10-19 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ γ−セクレターゼのピペリジニル及びピペラジニル調節物質
EA018862B1 (ru) * 2007-10-19 2013-11-29 Янссен Фармацевтика, Н.В. МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
CN101903334A (zh) * 2007-10-19 2010-12-01 詹森药业有限公司 Gsm中间体
WO2009052334A1 (fr) 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Modulateurs liés au carbone de la γ-sécrétase
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
KR20100135711A (ko) 2007-12-20 2010-12-27 엔비보 파마슈티칼즈, 인코퍼레이티드 사중치환된 벤젠
EP2488031A4 (fr) * 2009-10-16 2014-07-23 Merck Sharp & Dohme Dérivés d'éther diarylique comme inhibiteurs de la gamma-sécrétase n'agissant pas sur la voie notch
US8785481B2 (en) 2010-09-29 2014-07-22 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
CA2828764A1 (fr) * 2011-03-03 2012-09-07 Treventis Corporation Composes anti-amyloides et procedes
WO2015109109A1 (fr) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Morpholino-pyrimidines fusionnées et leurs procédés d'utilisation
US9802927B2 (en) 2015-06-10 2017-10-31 Denali Therapeutics, Inc. Oxadiazine compounds and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JP3802581B2 (ja) * 1995-03-01 2006-07-26 富山化学工業株式会社 新規なビフェニル誘導体またはその塩およびそれらを含有する抗炎症剤
CA2406383A1 (fr) 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Agents de reduction de a.beta.42
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
WO2004002939A2 (fr) * 2002-06-27 2004-01-08 Fujisawa Pharmaceutical Co., Ltd. Derives d'aminoalcool
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
WO2005110963A1 (fr) * 2004-05-19 2005-11-24 Cellzome Ag Acides (biphenyl-3-yl)-carboxyliques et derives de ceux-ci ainsi que leur utilisation en therapie
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
TW200621227A (en) * 2004-08-24 2006-07-01 Kissei Pharmaceutical Medicament for preventing or treating fatty liver
JP5155171B2 (ja) * 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物

Also Published As

Publication number Publication date
CR10375A (es) 2009-02-26
EP1849762B1 (fr) 2009-07-15
EP2021314A1 (fr) 2009-02-11
EA200802172A1 (ru) 2009-06-30
TNSN08413A1 (en) 2010-04-14
MX2008013445A (es) 2009-03-10
AU2007240335A1 (en) 2007-11-01
PE20080364A1 (es) 2008-05-16
BRPI0710656A2 (pt) 2011-08-16
NO20084517L (no) 2009-01-13
US7557244B2 (en) 2009-07-07
PL1849762T3 (pl) 2009-12-31
TW200815320A (en) 2008-04-01
UY30301A1 (es) 2007-08-31
JP2009544573A (ja) 2009-12-17
UA95952C2 (ru) 2011-09-26
MY148953A (en) 2013-06-14
ES2328616T3 (es) 2009-11-16
SMP200800061B (it) 2009-07-14
GT200900120A (es) 2009-11-16
CY1109399T1 (el) 2014-07-02
EP1849762A1 (fr) 2007-10-31
CA2650006A1 (fr) 2007-11-01
GEP20115269B (en) 2011-08-25
ES2400530T3 (es) 2013-04-10
AU2007240335B2 (en) 2013-05-02
DK1849762T3 (da) 2009-10-12
CN101687758B (zh) 2014-05-14
SI1849762T1 (sl) 2009-12-31
ZA200809856B (en) 2009-06-24
WO2007124394A1 (fr) 2007-11-01
KR101542255B1 (ko) 2015-08-06
PT1849762E (pt) 2009-09-16
JP5479088B2 (ja) 2014-04-23
NZ573000A (en) 2011-11-25
EP2021314B1 (fr) 2013-01-23
EA016129B1 (ru) 2012-02-28
SMAP200800061A (it) 2008-11-19
AP2008004656A0 (en) 2008-10-31
CN101687758A (zh) 2010-03-31
IL194790A (en) 2012-12-31
KR20090024679A (ko) 2009-03-09
AR060568A1 (es) 2008-06-25
EA016129B9 (ru) 2012-06-29
DE602006007810D1 (de) 2009-08-27
IL194852A0 (en) 2009-08-03
CR10451A (es) 2009-03-31
TWI399362B (zh) 2013-06-21
US20070293567A1 (en) 2007-12-20
CA2650006C (fr) 2016-08-23
IL194790A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
MA30475B1 (fr) Acides biphenyl carboxyliques substitutes et derives en resultant.
MA29514B1 (fr) Acides carboxylique (biphenyle) et leurs derives
MA27472A1 (fr) Acetyle 2-hydroxy-1, 3 diaminoalcanes
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
MA30420B1 (fr) Derives de terphenyle pour le traitment de la maladie d'alzheimer
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA30402B1 (fr) Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments
EA200802054A1 (ru) Ингибиторы фермента
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
EA200601660A1 (ru) Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
EA200800975A1 (ru) ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ
DE60326232D1 (de) Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
EP1817312A4 (fr) Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
MXPA06013503A (es) Uso de compuestos de kaureno en la manufactura de medicamentos.
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
TNSN08138A1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques